ReviewFrontiers in oral health2026
Outcomes of surgical, medication and combination therapies for cherubism: a systematic review and qualitative analysis.
Review in Frontiers in oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cherubism is a rare genetic fibro-osseous disorder characterized by symmetrical expansion of the maxilla and mandible. The lesions usually progress during childhood, stabilize around puberty, and regress in adulthood. Treatment strategies depend on lesion progression, tissue involvement, and patient concerns. This systematic review aimed to summarize treatment approaches, including surgery, medication, and combined modalities, and to provide an overview of clinical, radiographic, microscopic, and molecular findings. Evidence-based treatment decision-making in cherubism remains challenging, as no prior systematic review has comprehensively evaluated and compared the outcomes of surgical, pharmacologic, and combined approaches. Methods: This review followed PRISMA guidelines. PubMed, ScienceDirect, Cochrane, and SpringerLink databases were searched for studies on cherubism management. Eligible studies included cohort studies, retrospective analyses, case series, and case reports. Late-onset and reactivation cases were excluded. Eighteen studies published between 2015 and 2025 were included after evaluation for relevance, risk of bias, and outcome reliability. Results: A total of 18 studies comprising 36 patients with cherubism were analyzed. The age ranged from early childhood (around 4 years) to young adulthood (up to 21 years). Genetic testing for Conclusions: Cherubism management should be individualized based on disease grade and progression. Lower grades respond to conservative or pharmacologic therapy, whereas higher grades often require combined surgical and medical approaches using agents such as denosumab, imatinib, or tacrolimus. Advances in molecular insight and 3D-guided techniques support a trend toward personalized, grade-based treatment. Multicenter longitudinal studies remain essential to validate current strategies and establish standardized management guidelines for cherubism. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024623376, PROSPERO CRD42024623376.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.